ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature

Lynn Roy, Serene J. Samyesudhas, Martin Carrasco, Jun Li, Stancy Joseph, Richard Dahl, Karen Cowden Dahl

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Ovarian cancer is the most deadly gynecological malignancy since most patients have metastatic disease at the time of diagnosis. Therefore, identification of critical pathways that contribute to ovarian cancer progression is necessary to yield novel therapeutic targets. Recently we reported that the DNA binding protein ARID3B is overexpressed in human ovarian tumors. To determine if ARID3B has oncogenic functions in vivo, ovarian cancer cell lines stably expressing ARID3B were injected intraperitoneally into nude mice. Overexpression of ARID3B increased tumor burden and decreased survival. To assess how ARID3B contributes to the increased tumor growth in vivo, we identified ARID3B induced genes in tumor ascites cells. ARID3B induced expression of genes associated with metastasis and cancer stem cells (CD44, LGR5, PROM1 (CD133), and Notch2). Moreover, ARID3B increased the number of CD133+ (a cancer stem cell marker) cells compared to control cells. The increase in CD133+ cells resulting from ARID3B expression was accompanied by enhanced paclitaxel resistance. Our data demonstrate that ARID3B boosts production of CD133+ cells and increases ovarian cancer progression in vivo.

Original languageEnglish
Pages (from-to)8355-8366
Number of pages12
JournalOncotarget
Volume5
Issue number18
StatePublished - 2014

Fingerprint

Neoplastic Stem Cells
Tumor Burden
Ovarian Neoplasms
Genes
Neoplasms
Critical Pathways
DNA-Binding Proteins
Paclitaxel
Ascites
Nude Mice
Neoplasm Metastasis
Gene Expression
Cell Line
Survival
Growth

Keywords

  • Cancer stem cells
  • Metastasis
  • Ovarian cancer
  • Transcription factor
  • Xenografts

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Roy, L., Samyesudhas, S. J., Carrasco, M., Li, J., Joseph, S., Dahl, R., & Cowden Dahl, K. (2014). ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature. Oncotarget, 5(18), 8355-8366.

ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature. / Roy, Lynn; Samyesudhas, Serene J.; Carrasco, Martin; Li, Jun; Joseph, Stancy; Dahl, Richard; Cowden Dahl, Karen.

In: Oncotarget, Vol. 5, No. 18, 2014, p. 8355-8366.

Research output: Contribution to journalArticle

Roy, L, Samyesudhas, SJ, Carrasco, M, Li, J, Joseph, S, Dahl, R & Cowden Dahl, K 2014, 'ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature', Oncotarget, vol. 5, no. 18, pp. 8355-8366.
Roy L, Samyesudhas SJ, Carrasco M, Li J, Joseph S, Dahl R et al. ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature. Oncotarget. 2014;5(18):8355-8366.
Roy, Lynn ; Samyesudhas, Serene J. ; Carrasco, Martin ; Li, Jun ; Joseph, Stancy ; Dahl, Richard ; Cowden Dahl, Karen. / ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature. In: Oncotarget. 2014 ; Vol. 5, No. 18. pp. 8355-8366.
@article{1f193e2fa50449a385b26a3ba424b76a,
title = "ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature",
abstract = "Ovarian cancer is the most deadly gynecological malignancy since most patients have metastatic disease at the time of diagnosis. Therefore, identification of critical pathways that contribute to ovarian cancer progression is necessary to yield novel therapeutic targets. Recently we reported that the DNA binding protein ARID3B is overexpressed in human ovarian tumors. To determine if ARID3B has oncogenic functions in vivo, ovarian cancer cell lines stably expressing ARID3B were injected intraperitoneally into nude mice. Overexpression of ARID3B increased tumor burden and decreased survival. To assess how ARID3B contributes to the increased tumor growth in vivo, we identified ARID3B induced genes in tumor ascites cells. ARID3B induced expression of genes associated with metastasis and cancer stem cells (CD44, LGR5, PROM1 (CD133), and Notch2). Moreover, ARID3B increased the number of CD133+ (a cancer stem cell marker) cells compared to control cells. The increase in CD133+ cells resulting from ARID3B expression was accompanied by enhanced paclitaxel resistance. Our data demonstrate that ARID3B boosts production of CD133+ cells and increases ovarian cancer progression in vivo.",
keywords = "Cancer stem cells, Metastasis, Ovarian cancer, Transcription factor, Xenografts",
author = "Lynn Roy and Samyesudhas, {Serene J.} and Martin Carrasco and Jun Li and Stancy Joseph and Richard Dahl and {Cowden Dahl}, Karen",
year = "2014",
language = "English",
volume = "5",
pages = "8355--8366",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "18",

}

TY - JOUR

T1 - ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature

AU - Roy, Lynn

AU - Samyesudhas, Serene J.

AU - Carrasco, Martin

AU - Li, Jun

AU - Joseph, Stancy

AU - Dahl, Richard

AU - Cowden Dahl, Karen

PY - 2014

Y1 - 2014

N2 - Ovarian cancer is the most deadly gynecological malignancy since most patients have metastatic disease at the time of diagnosis. Therefore, identification of critical pathways that contribute to ovarian cancer progression is necessary to yield novel therapeutic targets. Recently we reported that the DNA binding protein ARID3B is overexpressed in human ovarian tumors. To determine if ARID3B has oncogenic functions in vivo, ovarian cancer cell lines stably expressing ARID3B were injected intraperitoneally into nude mice. Overexpression of ARID3B increased tumor burden and decreased survival. To assess how ARID3B contributes to the increased tumor growth in vivo, we identified ARID3B induced genes in tumor ascites cells. ARID3B induced expression of genes associated with metastasis and cancer stem cells (CD44, LGR5, PROM1 (CD133), and Notch2). Moreover, ARID3B increased the number of CD133+ (a cancer stem cell marker) cells compared to control cells. The increase in CD133+ cells resulting from ARID3B expression was accompanied by enhanced paclitaxel resistance. Our data demonstrate that ARID3B boosts production of CD133+ cells and increases ovarian cancer progression in vivo.

AB - Ovarian cancer is the most deadly gynecological malignancy since most patients have metastatic disease at the time of diagnosis. Therefore, identification of critical pathways that contribute to ovarian cancer progression is necessary to yield novel therapeutic targets. Recently we reported that the DNA binding protein ARID3B is overexpressed in human ovarian tumors. To determine if ARID3B has oncogenic functions in vivo, ovarian cancer cell lines stably expressing ARID3B were injected intraperitoneally into nude mice. Overexpression of ARID3B increased tumor burden and decreased survival. To assess how ARID3B contributes to the increased tumor growth in vivo, we identified ARID3B induced genes in tumor ascites cells. ARID3B induced expression of genes associated with metastasis and cancer stem cells (CD44, LGR5, PROM1 (CD133), and Notch2). Moreover, ARID3B increased the number of CD133+ (a cancer stem cell marker) cells compared to control cells. The increase in CD133+ cells resulting from ARID3B expression was accompanied by enhanced paclitaxel resistance. Our data demonstrate that ARID3B boosts production of CD133+ cells and increases ovarian cancer progression in vivo.

KW - Cancer stem cells

KW - Metastasis

KW - Ovarian cancer

KW - Transcription factor

KW - Xenografts

UR - http://www.scopus.com/inward/record.url?scp=84907967536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907967536&partnerID=8YFLogxK

M3 - Article

C2 - 25327563

AN - SCOPUS:84907967536

VL - 5

SP - 8355

EP - 8366

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 18

ER -